NEW YORK – Proteomics firm Biognosys said on Tuesday it is joining Cancer Scout, a recently launched project focused on developing an artificial intelligence-based multiomics solution to match cancer patients with therapies.
The research project is led by the University Medical Center Göttingen and Siemens Healthineers and funded through a €10 million ($11.5 million) grant from the German Federal Ministry of Education and Research. Within the program, researchers will combine genomics, proteomics, and pathology data to create a "digital biopsy" that captures the molecular changes within a patient's tumor. This digital biopsy, in turn, will inform diagnoses and personalized treatment options for cancer patients.
Schlieren, Switzerland-based Biognosys will provide its proprietary mass spectrometry technology, dubbed "Hyper Reaction Monitoring," to researchers within the project for large-scale proteomics analysis of cancers.
"Combining digital pathology with proteomics and other omics data is essential to identifying the full spectrum of molecular changes in tumors and enabl[ing] truly personalized cancer care," Philipp Strobel, University Hospital Göttingen's director of pathology, said in a statement.